U.S. Consumer Finance Stock News

Herbalife recently issued Q1 and full-year 2026 net sales growth guidance, projecting reported net sales to increase between 3.0% and 7.0% year over year for Q1 and 1.0% to 6.0% for 2026, prompting analysts to reassess the company’s turnaround prospects. The shift in analyst fair value estimates to US$16.50 highlights how updated guidance and evolving views on Herbalife’s turnaround are reshaping expectations for its business performance. We’ll now examine how Herbalife’s newly issued 2026...

Garmin’s Natural Cycles integration: what it could mean for the stock Garmin (GRMN) is drawing fresh attention after announcing a product integration with Natural Cycles, the FDA cleared birth control and fertility app, on select smartwatch models across multiple major markets. This partnership brings overnight skin temperature tracking from compatible Garmin devices directly into the Natural Cycles app, expanding Garmin’s women’s health capabilities and potentially strengthening the appeal...

AXIS Capital Holdings stock context AXIS Capital Holdings (AXS) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day decline of 0.38% and a past month decline of 1.90%. Over the past 3 months, AXIS Capital Holdings has recorded a 2.09% decline, while the 1 year total return stands at 16.11%, set against a market value of about US$7.5b. See our latest analysis for AXIS Capital Holdings. AXIS Capital Holdings’ recent 1 day and 3 month share...

In recent weeks, Agilent Technologies secured FDA approval for an expanded PD-L1 IHC 22C3 pharmDx cancer companion diagnostic indication and introduced the BioTek Cytation 9 cell imaging multimode reader, while the U.S. Supreme Court let stand rulings invalidating two of its CRISPR-related patents. This combination of a broader clinical diagnostic role alongside a new high-content lab instrument launch, set against a legal setback in gene-editing IP, reshapes how investors may view Agilent’s...

Assessing Deckers Outdoor after a mixed share price run Deckers Outdoor (DECK) has had a mixed share price run lately, with a 1 day decline, a modest gain over the past week, and negative returns over the month and past 3 months, prompting a closer look at fundamentals. See our latest analysis for Deckers Outdoor. At a share price of $100.26, Deckers Outdoor has seen recent share price pressure, with a 30 day share price return of 3.83% and a year to date share price return of 6.11%. Longer...

BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties to its rare disease pipeline and longer term R&D priorities. See our latest analysis for BioCryst Pharmaceuticals. At a share price of $9.59, BioCryst has seen a 30 day share price return of 13.09% and year to date share price return of 27.87%, while the 1 year total shareholder return of 48.22% points to building momentum around...

Flowers Foods (FLO) has drawn fresh attention after a series of executive moves, including CEO share sales, leadership departures, and wider organizational reshaping, alongside mixed results that combined higher sales with a net loss. See our latest analysis for Flowers Foods. The recent executive reshuffle and CEO share sale have come against a weak share price backdrop, with a 30 day share price return of 10.77% and a 1 year total shareholder return of 50.05% pointing to fading momentum as...

Covista Inc. recently expanded Michael Betz’s role to Chief Growth & Innovation Officer, adding oversight of the Marketing organization while he remains President of Walden University and leader of the Digital organization. This consolidation of growth, innovation, and marketing under a single leader marks a material shift in how Covista aims to coordinate its education brands and digital capabilities following the departure of Chief Marketing Officer Maurice Herrera. We’ll now examine how...

In March 2026, Sportradar AG announced it had expanded its multi-year agreement with Hard Rock Bet in the U.S., adding official PGA TOUR and UFC data, enhanced odds, and richer in-play betting features powered by assets gained through its IMG ARENA acquisition. The deeper tie-up showcases how Sportradar is bundling premium data rights with advanced visualizations and micro markets to become more embedded in operators’ core betting experiences. We’ll now examine how this expanded Hard Rock...

Life Time Group Holdings (LTH) is in focus after opening Life Time Eagle, its first athletic country club in Idaho. The 135,000-square-foot facility extends the brand into the Boise area. See our latest analysis for Life Time Group Holdings. The latest Idaho opening comes as momentum in the shares has picked up, with a 1 month share price return of 11.15% and a 3 year total shareholder return of 63.95%, suggesting sentiment has strengthened over time. If this kind of expansion has your...

The Professional Women’s Hockey League just set a U.S. attendance record for women’s hockey with a sold-out debut at Madison Square Garden, highlighting fresh demand for ice events at Madison Square Garden Sports (MSGS). See our latest analysis for Madison Square Garden Sports. The sold out PWHL debut comes at a time when MSGS has already seen strong momentum, with a 90 day share price return of 25.4% and a 1 year total shareholder return of 82.64%. This suggests investors are responding...

Event-driven look at Cohu stock Cohu (COHU) is back on investor radars after announcing US$30 million in follow on orders for its Eclipse test platform, which is configured with active thermal control for next generation high performance computing processors. One of these customers is also taking a subscription to Cohu’s PAICe prescriptive analytics software. This carries potential annual fees of about US$330,000 and ties recurring software revenue directly to equipment performance and...

Zimmer Biomet Holdings (ZBH) has drawn investor attention after recent trading left the stock with mixed returns, including a loss over the past year despite modest year to date gains. See our latest analysis for Zimmer Biomet Holdings. The recent 1 day share price return of 0.44% to US$91.40 and a modest 7 day gain sit against a 1 year total shareholder return decline of about 10%, indicating fading longer term momentum despite short term stability. If Zimmer Biomet’s move toward robotics...

Why Bristow Group’s latest quarter caught the market’s eye Bristow Group (VTOL) drew attention after reporting year on year revenue growth of 6.7%, while falling short of analysts’ expectations on EBITDA and EPS for the quarter. The company also highlighted continued expansion in its Government Services business, which management says is helping position Bristow as a multi mission aviation services provider with established roles in its core regions. See our latest analysis for Bristow...

Celsius Holdings (CELH) is back in focus after acquiring Rockstar Energy and Alani Nu, with analysts turning more positive as management points to revenue growth and potential margin gains during the ongoing integration. See our latest analysis for Celsius Holdings. The recent acquisitions and strong revenue print have not yet translated into share price strength. A 30 day share price return of 19.66% and a 90 day share price return of 32.84% have contributed to a year to date share price...

Wondering if Main Street Capital at around US$53.99 is offering fair value or a premium price today? This article breaks down what that number really means for you. The stock has a 1.9% return over the last 7 days, a 5.9% decline over 30 days, is down 12.6% year to date, and shows an 18.0% return over 1 year, 75.5% over 3 years and 90.0% over 5 years. Taken together, this gives a mixed picture of recent momentum and longer term performance. Recent coverage has focused on how Main Street...

In late March 2026, Denali Therapeutics announced that the FDA granted accelerated approval for AVLAYAH, the first blood-brain-barrier-crossing biologic for treating neurologic manifestations of Hunter syndrome in eligible pediatric patients, while in early April 2026 it received notice that Takeda will end their DNL593 co-development agreement, returning all rights and future obligations to Denali. Together, these developments highlight Denali’s transition toward independently advancing its...

In March 2026, BlackSky Technology Inc. was awarded a multi-year, sole-source US$99 million U.S. government IDIQ contract from the Air Force Research Laboratory to design advanced large-aperture optical payloads for next-generation Earth observation and space domain awareness satellites. The contract highlights BlackSky’s role in developing satellites that act as in-orbit data storage and processing hubs compatible with AI-enabled space data centers, potentially expanding its relevance...

Why General Electric (GE) Is Back On Investor Radars General Electric (GE) is drawing attention after a period where the share price and fundamentals appear out of sync, with recent share performance contrasting with its revenue and net income profile. See our latest analysis for General Electric. GE’s recent 10% 30 day share price decline and similar 90 day share price return sit against a very strong 1 year total shareholder return of 71.3% and 3 year total shareholder return near 3x. This...

Anthropic, Microsoft and other major tech and financial firms have launched Project Glasswing to address critical software vulnerabilities using advanced AI models. The initiative includes early access to Anthropic’s unreleased Claude Mythos Preview model, focused on finding and fixing weaknesses in core digital infrastructure. Project Glasswing is positioned as an industry level effort to use next generation AI for defensive cybersecurity rather than offensive use. For investors watching...

Recent performance snapshot for VICI Properties VICI Properties (VICI) has drawn attention after a recent share price move, with the stock last closing at $27.83. Short term returns are mixed, with a 0.6% gain over the past day and 1.9% over the past week. See our latest analysis for VICI Properties. While the recent 1-day and 7-day share price returns show a modest pick up in momentum, the 30-day share price return of a 6.2% decline and relatively flat 1-year total shareholder return of...

Everpure, listed as NYSE:PSTG, has announced a corporate rebranding under the short ticker "P". The new ticker is intended to reflect the company’s broader vision around intelligent data and storage management for the AI era. The change marks a shift in emphasis from pure storage offerings toward a wider data management platform identity. Everpure has built its identity around storage solutions, and the move to the ticker "P" signals a wider focus on managing data as a core asset in...

Amgen has reported positive Phase 3 results for a new subcutaneous, on-body injector formulation of Tepezza for Thyroid Eye Disease. The late stage trial found that the on-body injector delivered comparable efficacy and safety to the already approved intravenous version. This new formulation is aimed at offering a more convenient treatment option as competition in Thyroid Eye Disease increases. For investors watching NasdaqGS:AMGN, this update comes with the shares trading around $340.0 and...

Cal-Maine Foods (CALM) is back in focus after its latest quarterly update, which combined a sharp year-on-year drop in sales and net income with a reduced dividend and a continued push for selective acquisitions. See our latest analysis for Cal-Maine Foods. The share price has softened following weaker quarterly sales and a lower dividend, with a 30 day share price return showing a decline of 14.02% and a 1 year total shareholder return showing a decline of 7.07%, although the 3 and 5 year...